/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
With a market cap of $20.4 billion, Biogen Inc. (BIIB) is a leading biopharmaceutical company specializing in treatments for neurological, rare, and immunological diseases. Headquartered in Cambridge, Massachusetts, Biogen has built its reputation as a pioneer in neuroscience, with decades of leadership in multiple sclerosis therapies, including Tecfidera, Avonex, and Tysabri.
Shares of this leading biotechnology company have significantly underperformed the broader market over the past year. BIIB has declined 32.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 14.3%. In 2025, BIIB stock is down 9.1%, compared to the SPX’s 8.7% rise on a YTD basis.